CD274 and metastatic melanoma: A monotherapy trial assessing atezolizumab in metastatic melanoma reported a median overall survival (OS) of 36% with a disease control rate of 45%, ultimately determining that patients with higher PD-L1 expression correlated with better therapy response [34].